

Accepted Manuscript

Title: Why Has a Run-in Period Been a Design Element in Most Landmark Clinical Trials? Analysis of the Critical Role of Run-in Periods in Drug Development

Author: Milton Packer

PII: S1071-9164(17)30620-6
DOI: <http://dx.doi.org/doi: 10.1016/j.cardfail.2017.07.401>
Reference: YJCAF 4013

To appear in: *Journal of Cardiac Failure*

Received date: 16-5-2017
Revised date: 18-6-2017
Accepted date: 24-7-2017

Please cite this article as: Milton Packer, Why Has a Run-in Period Been a Design Element in Most Landmark Clinical Trials? Analysis of the Critical Role of Run-in Periods in Drug Development, *Journal of Cardiac Failure* (2017), <http://dx.doi.org/doi: 10.1016/j.cardfail.2017.07.401>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Why Has a Run-In Period Been a Design Element in Most Landmark Clinical Trials? Analysis of the Critical Role of Run-In Periods in Drug Development

Milton Packer MD

Baylor Heart and Vascular Institute, Baylor University
Medical Center, Dallas, TX, USA

Corresponding Author: Milton Packer, M.D., Baylor Heart and Vascular Institute,
Baylor University Medical Center, 621 N. Hall Street, Dallas TX 75226

Email: milton.packer@baylorhealth.edu

Disclosures: Dr. Packer was the principal investigator of many landmark clinical trials with a run-in period, but these were completed and presented years ago, and he has no recent or current personal, professional or institutional financial relationship with the sponsors of these trials (GlaxoSmithKline, Novartis and Boots Pharmaceuticals). Dr. Packer has recently consulted for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorientis, Celyad, Daiichi Sankyo, Relypsa and Sanofi.

Word count: original paper shortened from 1477 to 1303, but new paragraph added; final word count of revised submission is 1444.

Download English Version:

<https://daneshyari.com/en/article/5614055>

Download Persian Version:

<https://daneshyari.com/article/5614055>

[Daneshyari.com](https://daneshyari.com)